원문정보
초록
영어
Airway inflammatory diseases like asthma is a global public health concern due to their chronic inflammatory effects on the respiratory mucosa. Recently, the application of molecular hydrogen (H₂) has been recognized for its antioxidant and anti-inflammatory properties. In this study, we investigated the therapeutic potential of H₂ in airway inflammation using an ovalbumin (OVA)-induced BALB/c mouse model of allergic asthma. Female BALB/c mice were sensitized and challenged with OVA to induce airway inflammation and thirty mice were randomly divided into five groups: NT (non-treatment), HTC (3% H₂ treatment only), NC (negative control, OVA only), PC (positive control, OVA + intranasal 1 mg/ml salbutamol 50μl), and HT (H₂ treatment, OVA + inhaled 3% H₂). Various inflammatory and oxidative stressinduced markers such as WBC and its differential counts, lung histology, reactive oxygen species (ROS), nitric oxide (NO), glutathione peroxidase (GPx), and catalase (CAT), cytokine levels such as interferongamma (IFN-γ), interleukin (IL)-4, tumor necrosis factor-alpha (TNF-α), (IL)-10, granulocyte-macrophage colony-stimulating factor (GM-CSF), (IL)-5, (IL)-13, and total immunoglobulin E (IgE) levels were investigated. Our results demonstrated that inhaled H₂ significantly reduced inflammatory cell infiltration, oxidative stress markers, and pro-inflammatory cytokines expression while upregulating antioxidant enzyme activity. Additionally, H₂ also significantly decreased serum IgE levels, a marker of allergic inflammation. Collectively, our findings suggest that H₂ inhalation could be a promising treatment option for airway inflammation, offering a novel approach with potential clinical applications.